- Home
- CRSP vs OMAB Comparison
CRSP vs OMAB Comparison
Compare CRSP & OMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- OMAB
- Stock Information
- Founded
- CRSP 2013
- OMAB 1998
- Country
- CRSP Switzerland
- OMAB Mexico
- Employees
- CRSP N/A
- OMAB N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- OMAB Aerospace
- Sector
- CRSP Health Care
- OMAB Consumer Discretionary
- Exchange
- CRSP Nasdaq
- OMAB Nasdaq
- Market Cap
- CRSP 3.4B
- OMAB 3.5B
- IPO Year
- CRSP 2016
- OMAB 2006
- Fundamental
- Price
- CRSP $40.53
- OMAB $76.64
- Analyst Decision
- CRSP Buy
- OMAB Buy
- Analyst Count
- CRSP 19
- OMAB 2
- Target Price
- CRSP $77.13
- OMAB $94.00
- AVG Volume (30 Days)
- CRSP 1.8M
- OMAB 70.3K
- Earning Date
- CRSP 02-19-2025
- OMAB 02-21-2025
- Dividend Yield
- CRSP N/A
- OMAB 11.43%
- EPS Growth
- CRSP N/A
- OMAB 2.12
- EPS
- CRSP N/A
- OMAB 0.66
- Revenue
- CRSP $202,829,000.00
- OMAB $748,989,666.00
- Revenue This Year
- CRSP N/A
- OMAB N/A
- Revenue Next Year
- CRSP $724.16
- OMAB $6.09
- P/E Ratio
- CRSP N/A
- OMAB $14.55
- Revenue Growth
- CRSP 19.31
- OMAB 1.76
- 52 Week Low
- CRSP $36.52
- OMAB $59.08
- 52 Week High
- CRSP $91.10
- OMAB $90.53
- Technical
- Relative Strength Index (RSI)
- CRSP 44.09
- OMAB 62.94
- Support Level
- CRSP $36.52
- OMAB $70.16
- Resistance Level
- CRSP $40.99
- OMAB $78.30
- Average True Range (ATR)
- CRSP 1.78
- OMAB 2.30
- MACD
- CRSP 0.23
- OMAB 0.48
- Stochastic Oscillator
- CRSP 51.68
- OMAB 84.47
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About OMAB Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS
Grupo Aeroportuario del Centro Norte SAB de CV operates airports in the central region of Mexico. The airport is in Monterrey, which serves nearly half of the company's total passengers. In addition, the company manages two hotels and one industrial park.